Surgical Treatment: Green Light Laser

2017 ◽  
pp. 105-116
Author(s):  
Clarissa Martyn-Hemphill ◽  
Srinath Chandrasekera ◽  
Gordon Muir
2018 ◽  
Vol 17 (2) ◽  
pp. e180-e182
Author(s):  
M. Marchioni ◽  
L. Cindolo ◽  
C. De Nunzio ◽  
F. Greco ◽  
P. Destefanis ◽  
...  

2011 ◽  
Vol 1 (7) ◽  
pp. 162-163
Author(s):  
J. H. Roelink ◽  
I. Hofmeester ◽  
G. J. Molijn ◽  
O. van Balen ◽  
H. E. Dijkema

2007 ◽  
Vol 52 (6) ◽  
pp. 1632-1637 ◽  
Author(s):  
Elmar Heinrich ◽  
Frank Schiefelbein ◽  
Georg Schoen

2012 ◽  
Vol 14 (5) ◽  
pp. 720-725 ◽  
Author(s):  
Hui Ding ◽  
Wan Du ◽  
Ze-Ping Lu ◽  
Zhen-Xing Zhai ◽  
Han-Zhang Wang ◽  
...  

Urology ◽  
2011 ◽  
Vol 78 (3) ◽  
pp. S265-S266
Author(s):  
J. Dockray ◽  
M. Rieken ◽  
S. Chandrasekara ◽  
K. Walsh ◽  
F. Liberale ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e028855 ◽  
Author(s):  
Shicong Lai ◽  
Panxin Peng ◽  
Tongxiang Diao ◽  
Huimin Hou ◽  
Xuan Wang ◽  
...  

ObjectiveTo assess the efficacy and safety of green-light laser photoselective vaporisation of the prostate (PVP) compared with transurethral resection of the prostate (TURP) for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).DesignSystematic review and meta-analysis, conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.Data sourcesPubMed, EMBASE, the Cochrane Library until October 2018.Eligibility criteriaRandomised controlled trials and prospective studies comparing the safety and efficacy of PVP versus TURP for LUTS manifesting through BPH.Data extraction and synthesisPerioperative parameters, complications rates and functional outcomes including treatment-related adverse events such as International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), postvoid residual (PVR), quality of life (QoL) and International Index of Erectile Function (IIEF).Results22 publications consisting of 2665 patients were analysed. Pooled analysis revealed PVP is associated with reduced blood loss, transfusion, clot retention, TUR syndrome, capsular perforation, catheterisation time and hospitalisation, but also with a higher reintervention rate and longer intervention duration (all p<0.05). No significant difference in IPSS, Qmax, QoL, PVR or IIEF at 3, 24, 36 or 60 months was identified. There was a significant difference in QoL at 6 months (MD=−0.08; 95% CI −0.13 to −0.02; p=0.007), and IPSS (MD = −0.10; 95% CI −0.15 to −0.05; p<0.0001) and Qmax (MD=0.62; 95% CI 0.06 to 1.19; p=0.03) at 12 months, although these differences were not clinically relevant.ConclusionPVP is an effective alternative, holding additional safety benefits. PVP has equivalent long-term IPSS, Qmax, QoL, PVR, IIEF efficacy and fewer complications. The main drawbacks are dysuria and reintervention, although both can be managed with non-invasive techniques. The additional shortcoming is that PVP does not acquire histological tissue examination which removes an opportunity to identify prostate cancer.


2018 ◽  
Vol 17 (2) ◽  
pp. e1961
Author(s):  
C. Pascoe ◽  
D. Christidis ◽  
T. Manning ◽  
B. Lamb ◽  
D. Murphy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document